Connect Sign In
This issue highlights milestones in ARUP’s history, gives a glimpse into the company’s future, and includes a special feature: a video of ARUP founders and current leaders reminiscing and celebrating.
ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs.
Nicola Longo, who with his wife, Marzia Pasquali, is credited with expanding screening for a treatable metabolic disorder, is leaving for UCLA while Pasquali stays at ARUP to continue key projects.
A new partnership between ARUP and connectivity provider ELLKAY aims to give health systems the testing support, guidance, and technology needed to establish or expand lab outreach operations.
The ARUP Consult Laboratory Testing for Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder topic now includes exome and genome sequencing as a first- or second-tier test.
The FDA’s proposed rule to regulate lab-developed tests will force labs to halt essential testing, harming children and patients with cancer and rare diseases, says ARUP’s Jonathan Genzen, MD, PhD.
Of the ARUP clients who participated in the 2023 client satisfaction survey, 93% had a favorable impression of the company, up from 91% in 2022.
ARUP’s returnships are short-term, paid opportunities designed for skilled professionals with an employment gap of one year or longer for any reason including military service or family obligation.
Nearly 85% of respondents to an ARUP survey believe the FDA’s proposed rule to regulate lab-developed tests will negatively impact their labs. Only 3% believe they have the financial resources to comply.
ARUP is committed to continue offering quality, esoteric testing that can aid patients with rare diseases on their often difficult diagnostic journeys.
